日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes

HNRNPH1通过调控细胞周期基因的剪接驱动胶质母细胞瘤的进展

Villa, Genaro R; Alimonti, Paolo; Toker, Joseph S; Piranlioglu, Raziye; Karkoski, Mikayla A; Mazzetti, Debora; Ben Mrid, Reda; El Guendouzi, Sara; Lauinger, Alexa; Chiocca, Andrew N; El Fatimy, Rachid; Chiocca, E Antonio; Mineo, Marco

Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

lncRNA NEAT1在接受免疫检查点抑制剂治疗的癌症患者中的临床意义

Toker, Joseph; Iorgulescu, J Bryan; Ling, Alexander L; Villa, Genaro R; Gadet, Josephina A M A; Parida, Laxmi; Getz, Gad; Wu, Catherine J; Reardon, David A; Chiocca, E Antonio; Mineo, Marco

Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource

共享信息:源自患者的、经过深度表征的胶质母细胞瘤细胞系资源

Villa, Genaro R; Mischel, Paul S

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

PDGFRβ 转录的去抑制促进胶质母细胞瘤患者对 EGFR 酪氨酸激酶抑制剂产生获得性耐药性

Akhavan David, Pourzia Alexandra L, Nourian Alex A, Williams Kevin J, Nathanson David, Babic Ivan, Villa Genaro R, Tanaka Kazuhiro, Nael Ali, Yang Huijun, Dang Julie, Vinters Harry V, Yong William H, Flagg Mitchell, Tamanoi Fuyuhiko, Sasayama Takashi, James C David, Kornblum Harley I, Cloughesy Tim F, Cavenee Webster K, Bensinger Steven J, Mischel Paul S

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

EGFR 突变诱导的 Max 选择性剪接促进脑癌中糖酵解肿瘤的生长

Babic Ivan, Anderson Erik S, Tanaka Kazuhiro, Guo Deliang, Masui Kenta, Li Bing, Zhu Shaojun, Gu Yuchao, Villa Genaro R, Akhavan David, Nathanson David, Gini Beatrice, Mareninov Sergey, Li Rui, Camacho Carolina Espindola, Kurdistani Siavash K, Eskin Ascia, Nelson Stanley F, Yong William H, Cavenee Webster K, Cloughesy Timothy F, Christofk Heather R, Black Douglas L, Mischel Paul S

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

mTOR 复合物 2 通过 FoxO 乙酰化和 c-Myc 上调控制胶质母细胞瘤中的糖酵解代谢

Masui Kenta, Tanaka Kazuhiro, Akhavan David, Babic Ivan, Gini Beatrice, Matsutani Tomoo, Iwanami Akio, Liu Feng, Villa Genaro R, Gu Yuchao, Campos Carl, Zhu Shaojun, Yang Huijun, Yong William H, Cloughesy Timothy F, Mellinghoff Ingo K, Cavenee Webster K, Shaw Reuben J, Mischel Paul S

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

mTOR 激酶抑制剂 CC214-1 和 CC214-2 优先阻断 EGFRvIII 激活的胶质母细胞瘤的生长

Gini Beatrice, Zanca Ciro, Guo Deliang, Matsutani Tomoo, Masui Kenta, Ikegami Shiro, Yang Huijun, Nathanson David, Villa Genaro R, Shackelford David, Zhu Shaojun, Tanaka Kazuhiro, Babic Ivan, Akhavan David, Lin Kelly, Assuncao Alvaro, Gu Yuchao, Bonetti Bruno, Mortensen Deborah S, Xu Shuichan, Raymon Heather K, Cavenee Webster K, Furnari Frank B, James C David, Kroemer Guido, Heath James R, Hege Kristen, Chopra Rajesh, Cloughesy Timothy F, Mischel Paul S